New drug cocktail aims to boost stem cell transplant success in myeloma
NCT ID NCT01054196
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding lenalidomide (Revlimid) to the standard high-dose melphalan before an autologous stem cell transplant can improve outcomes for people with relapsed multiple myeloma. In the first phase, researchers find the safest dose of lenalidomide to combine with melphalan. In the second phase, they measure how long the response lasts. About 52 participants are enrolled, and after transplant, they continue on a standard low dose of lenalidomide to maintain the effect.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- lenalidomide (Revlimid) and melphalan
- What this could lead to
- If successful, this could lead to a more effective preparative regimen for stem cell transplant, potentially extending remission in relapsed multiple myeloma.
- What could go wrong
- This is an early-phase trial with only 52 participants, so results may not apply broadly. Adding lenalidomide to high-dose chemotherapy also raises risks of severe side effects like low blood counts and infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Weill Cornell Medical College
New York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- A guided path back to work after blood cancer: a trial tests the impact